Bellicum Pharmaceuticals Inc (BLCM) Receives Consensus Rating of “Hold” from Brokerages

Shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) have been assigned an average recommendation of “Hold” from the nine ratings firms that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $16.20.

Several analysts have commented on BLCM shares. ValuEngine cut shares of Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday. Wells Fargo & Co cut shares of Bellicum Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $6.00 target price for the company. in a research note on Wednesday, January 31st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $10.00 target price (down from $12.00) on shares of Bellicum Pharmaceuticals in a research note on Wednesday, January 31st. Zacks Investment Research cut shares of Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, January 12th. Finally, SunTrust Banks lowered their target price on shares of Bellicum Pharmaceuticals to $18.00 and set a “buy” rating for the company in a research note on Wednesday, January 31st.

Bellicum Pharmaceuticals (NASDAQ BLCM) opened at $5.61 on Tuesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.08 and a current ratio of 6.08. Bellicum Pharmaceuticals has a 12 month low of $5.02 and a 12 month high of $15.55. The firm has a market cap of $184.90, a P/E ratio of -1.88 and a beta of 0.70.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.74) by $0.03. The business had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.03 million. During the same period last year, the business earned ($0.66) earnings per share. The company’s revenue for the quarter was up 18.2% on a year-over-year basis. research analysts predict that Bellicum Pharmaceuticals will post -2.93 earnings per share for the current year.

In other news, major shareholder Bros. Advisors Lp Baker sold 260,600 shares of the business’s stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $8.63, for a total transaction of $2,248,978.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Alan A. Musso sold 17,117 shares of the business’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $9.33, for a total transaction of $159,701.61. Following the sale, the chief financial officer now directly owns 31,585 shares of the company’s stock, valued at $294,688.05. The disclosure for this sale can be found here. Insiders sold a total of 1,165,145 shares of company stock valued at $9,696,662 over the last ninety days. 18.77% of the stock is owned by corporate insiders.

Several large investors have recently bought and sold shares of the stock. Principal Financial Group Inc. lifted its holdings in shares of Bellicum Pharmaceuticals by 1.8% during the 2nd quarter. Principal Financial Group Inc. now owns 84,820 shares of the biopharmaceutical company’s stock valued at $991,000 after acquiring an additional 1,482 shares in the last quarter. ProShare Advisors LLC lifted its holdings in shares of Bellicum Pharmaceuticals by 14.9% during the 2nd quarter. ProShare Advisors LLC now owns 19,393 shares of the biopharmaceutical company’s stock valued at $227,000 after acquiring an additional 2,513 shares in the last quarter. Nationwide Fund Advisors lifted its holdings in shares of Bellicum Pharmaceuticals by 30.4% during the 2nd quarter. Nationwide Fund Advisors now owns 15,530 shares of the biopharmaceutical company’s stock valued at $181,000 after acquiring an additional 3,620 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Bellicum Pharmaceuticals by 26.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,319 shares of the biopharmaceutical company’s stock valued at $261,000 after acquiring an additional 4,684 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in shares of Bellicum Pharmaceuticals by 6.6% during the 2nd quarter. Wells Fargo & Company MN now owns 81,065 shares of the biopharmaceutical company’s stock valued at $947,000 after acquiring an additional 4,984 shares in the last quarter. Institutional investors and hedge funds own 55.24% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/02/06/bellicum-pharmaceuticals-inc-blcm-receives-consensus-rating-of-hold-from-brokerages.html.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Analyst Recommendations for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply